Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma

2012 ◽  
Vol 44 (7) ◽  
pp. 610-616 ◽  
Author(s):  
Thomas Decaens ◽  
Alain Luciani ◽  
Emmanuel Itti ◽  
Anne Hulin ◽  
Françoise Roudot-Thoraval ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Hepatocellular Carcinoma ◽  
Treatment Naïve

Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study

2016 ◽  
Vol 77 (2) ◽  
pp. 243-250 ◽  
Author(s):  
Hiroaki Nagamatsu ◽  
Shuji Sumie ◽  
Takashi Niizeki ◽  
Nobuyoshi Tajiri ◽  
Hideki Iwamoto ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Hepatic Arterial Infusion ◽  
Advanced Hepatocellular Carcinoma ◽  
Arterial Infusion ◽  
Multicenter Phase

A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma

2008 ◽  
Vol 26 (4) ◽  
pp. 381-386 ◽  
Author(s):  
Allen L. Cohn ◽  
J. William Myers ◽  
Steven Mamus ◽  
Charles Deur ◽  
Steven Nicol ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Hepatocellular Carcinoma

scholarly journals Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study

Oncology ◽  
2013 ◽  
Vol 85 (1) ◽  
pp. 44-52 ◽  
Author(s):  
Chih-Hung Hsu ◽  
Yoon Koo Kang ◽  
Tsai-Shen Yang ◽  
Chia-Tung Shun ◽  
Yu-Yun Shao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Hepatocellular Carcinoma ◽  
First Line ◽  
First Line Therapy ◽  
Asian Patients ◽  
Multicenter Phase ◽  
Line Therapy

Phase II study of sorafenib plus tegafur/uracil (UFT) in patients with advanced hepatocellular carcinoma (HCC)

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 15664-15664 ◽  
Author(s):  
Y. Shen ◽  
Y. Shao ◽  
C. Hsu ◽  
C. Hsu ◽  
Z. Lin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Advanced Hepatocellular Carcinoma

Phase II study of intrabuccally-administered amplitude-modulated electromagnetic fields in patients with advanced hepatocellular carcinoma

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15573-e15573
Author(s):  
F. P. Costa ◽  
A. C. de Oliveira ◽  
R. Meirelles ◽  
M. M. Machado ◽  
R. Surjan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Electromagnetic Fields ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Progression Free Survival ◽  
Hepatic Function ◽  
Advanced Hepatocellular Carcinoma ◽  
Free Survival ◽  
Advanced Hcc ◽  
Independent Review

e15573 Background: Over the past few years we have identified tumor-specific frequencies for several common forms of cancer. The goal of this study was to assess the tolerability and effectiveness of electromagnetic fields amplitude-modulated at tumor-specific frequencies and administered by means of an intrabuccal spoon-shaped probe in patients with advanced hepatocellular carcinoma (HCC). Methods: From October 2005 to July 2007, patients with advanced HCC and Child-Pugh A or B were recruited in a phase II study. Three daily 60 min outpatient treatments were administered until disease progression or death. Imaging studies were performed every eight weeks. The primary efficacy end point was progression-free survival ≥ 6 months. Secondary efficacy end points were progression-free survival and overall survival. Results: A total of 41 patients were enrolled, 17 had Child-Pugh A, 20 Child-Pugh B disease. The median age was 64.0 years. Seventeen patients (34.1%) were progression-free for more than 6 months. Median progression-free and overall survivals were 4.8 months (95% CI 2.3–6.0) and 6.9 months (95 CI 4.8–11.1). As of December 2008, four patients are alive and two patients, who are still undergoing therapy, remain progression-free for 30.4 and 30.7 months, respectively. Four patients had partial response (9.8%) and sixteen had stable disease for at least 12 weeks (39.0%) according to the RECIST criteria resulting in 48.8% disease control. All responses were confirmed by independent review. There were no NCI grade 2, 3 or 4 toxicities. One patient developed grade 1 mucositis and one patient grade 1 fatigue. Conclusions: In patients with advanced HCC and impaired hepatic function, treatment with amplitude-modulated electromagnetic fields is safe, well tolerated, and shows evidence of anti-tumor effects, which are long-lasting in some patients. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document